Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
COCP 
Cocrystal Pharma Inc (COCP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: COCP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8
1 Year Target Price $8
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -35.15% | Avg. Invested days 25 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.16M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 2 | Beta 2.12 | 52 Weeks Range 1.12 - 3.26 | Updated Date 06/30/2025 |
52 Weeks Range 1.12 - 3.26 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -53.96% | Return on Equity (TTM) -106.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10685147 | Price to Sales(TTM) 92.45 |
Enterprise Value 10685147 | Price to Sales(TTM) 92.45 | ||
Enterprise Value to Revenue 17.89 | Enterprise Value to EBITDA 0.66 | Shares Outstanding 10173800 | Shares Floating 6554769 |
Shares Outstanding 10173800 | Shares Floating 6554769 | ||
Percent Insiders 36.35 | Percent Institutions 7.36 |
Analyst Ratings
Rating 2 | Target Price 8 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cocrystal Pharma Inc
Company Overview
History and Background
Cocrystal Pharma, Inc. (formerly BioCryst Pharmaceuticals Discovery) was incorporated in 2007. It focuses on discovering and developing novel antiviral therapeutics. The company has evolved through research collaborations and clinical trials.
Core Business Areas
- Drug Discovery and Development: Cocrystal Pharma focuses on discovering and developing antiviral therapeutics using its structure-based drug discovery platform. This includes identifying and developing compounds that inhibit viral replication.
- Licensing and Partnerships: The company seeks partnerships and licensing agreements to further develop and commercialize its antiviral compounds.
Leadership and Structure
The leadership team includes the CEO, CFO, and Chief Scientific Officer. The organizational structure consists of research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- CC-42344: A PBK inhibitor to be developed as a broad-spectrum antiviral for human rhinoviruses (HRV), coronaviruses, and noroviruses. Market share and revenue data is not readily available. Competitors are companies developing similar broad-spectrum antiviral therapies.
- CC-223: Broad-spectrum protease inhibitor targeting replication of noroviruses. Market share and revenue data is not readily available. Competitors are companies developing similar broad-spectrum antiviral therapies.
- CC-31244: Broad-spectrum inhibitor for influenza A and B viruses. Market share and revenue data is not readily available. Competitors include companies developing similar influenza treatments, such as Roche (Tamiflu) and BioCryst (Rapivab).
Market Dynamics
Industry Overview
The antiviral drug market is driven by the ongoing need for treatments against emerging and existing viral infections. The market is competitive, with both established pharmaceutical companies and smaller biotech firms vying for market share.
Positioning
Cocrystal Pharma is a smaller player focusing on novel antiviral discovery. Its competitive advantage lies in its structure-based drug discovery platform, which aims to identify more effective and targeted antiviral compounds.
Total Addressable Market (TAM)
The global antiviral drug market is projected to reach hundreds of billions of dollars. Cocrystal Pharma is targeting specific viral infections, so it aims to capture a portion of this large market.
Upturn SWOT Analysis
Strengths
- Structure-based drug discovery platform
- Novel antiviral compound pipeline
- Potential for broad-spectrum antiviral therapies
Weaknesses
- Limited financial resources
- Dependence on partnerships and licensing agreements
- Early stage of drug development
Opportunities
- Partnerships with larger pharmaceutical companies
- Government funding for antiviral research
- Addressing unmet needs in antiviral treatment
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- MRK
- GILD
- JNJ
Competitive Landscape
Cocrystal Pharma faces significant competition from larger, more established pharmaceutical companies. Its success depends on the differentiation and effectiveness of its antiviral compounds.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to advancement of its pipeline candidates through pre-clinical and clinical stages.
Future Projections: Future growth depends on successful clinical trials and commercialization of its antiviral compounds.
Recent Initiatives: Recent initiatives include advancing its antiviral programs through pre-clinical and clinical development, and securing partnerships to fund development.
Summary
Cocrystal Pharma is a small biotech company focusing on antiviral drug discovery. Its structure-based drug discovery platform is a strength, but it faces financial constraints and competition. Successful clinical trials and partnerships are crucial for its future growth. Securing adequate funding and mitigating clinical trial risks will be critical.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- Third-party financial data providers
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on individual due diligence and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cocrystal Pharma Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 2011-05-19 | Co-Founder, Co-CEO & President Dr. Sam Lee Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://www.cocrystalpharma.com |
Full time employees 11 | Website https://www.cocrystalpharma.com | ||
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.